Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice

Abstract

Background Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been suggested to prevent the development of metabolic disorders. However, their individual role in treating hyperglycemia and the mechanism of action regarding gut microbiome and metabolome in the context of diabetes remain unclear. Results Supplementation of DHA and EPA attenuated hyperglycemia and insulin resistance without changing body weight in db/db mice while the ameliorative effect appeared to be more pronounced for EPA. DHA/EPA supplementation reduced the abundance of the lipopolysaccharide-containing Enterobacteriaceae whereas elevated the family Coriobacteriaceae negatively correlated with glutamate level, genera Barnesiella and Clostridium XlVa associated with bile acids production, beneficial Bifidobacterium and Lactobacillus, and SCFA-producing species. The gut microbiome alterations co-occurred with the shifts in the metabolome, including glutamate, bile acids, propionic/butyric acid, and lipopolysaccharide, which subsequently relieved β cell apoptosis, suppressed hepatic gluconeogenesis, and promoted GLP-1 secretion, white adipose beiging, and insulin signaling. All these changes appeared to be more evident for EPA. Furthermore, transplantation with DHA/EPA-mediated gut microbiota mimicked the ameliorative effect of DHA/EPA on glucose homeostasis in db/db mice, together with similar changes in gut metabolites. In vitro, DHA/EPA treatment directly inhibited the growth of Escherichia coli (Family Enterobacteriaceae) while promoted Coriobacterium glomerans (Family Coriobacteriaceae), demonstrating a causal effect of DHA/EPA on featured gut microbiota. Conclusions DHA and EPA dramatically attenuated hyperglycemia and insulin resistance in db/db mice, which was mediated by alterations in gut microbiome and metabolites linking gut to adipose, liver and pancreas. These findings shed light into the gut-organs axis as a promising target for restoring glucose homeostasis and also suggest a better therapeutic effect of EPA for treating diabetes.

Bacteroides acidifaciens in the gut plays a protective role against CD95-mediated liver injury

“…Previous studies showed that bile acids, SCFAs, and glutathione were involved in hepatocyte apoptosis. 34 , 39 , 40 The present study performed a metabonomic analysis of SCFAs and bile acids in the livers of Van- and Gen-treated mice (Supplementary Figures S7, S8). The levels of some SCFAs and bile acids in the livers of the Gen-treated mice were significantly higher than the Van-treated mice (Supplementary Figures S7c and S8).…”

Fucoidan protects the pancreas and improves glucose metabolism through inhibiting inflammation and endoplasmic reticulum stress in T2DM rats

“…The normal control group was given a normal chow diet (AIN-93 diet), while rats of the model control group were given a high fat diet (HFD) for 8 weeks (Table 1). 22–25 Then, the rats of the model control group were overnight fasted, weighed, and injected intraperitoneally with STZ at 35 mg kg −1 . The rats of the normal control group received only the same volume of citrate buffer.…”

Lingguizhugan Decoction Targets Intestinal Microbiota and Metabolites to Reduce Insulin Resistance in High-Fat Diet Rats

“…Primary and secondary bile acids can stimulate the farnesoid X receptor and GPCR-19 to regulate glucose metabolism. 41 Conjugated primary bile acids (glucocholic acid, taurine, etc.) were positively associated with T2DM risk, 42 which is consistent with our observations.…”